A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.
The trial objective was to test whether a new mechanism of action would effectively treat migraine headaches and to select a dose range for further investigation. The motivation for a group sequential, adaptive, placebo-controlled trial design was (1) limited information about where across the range of seven doses to focus attention, (2) a need to limit sample size for a complicated inpatient treatment and (3) a desire to reduce exposure of patients to ineffective treatment. A design based on group sequential and up and down designs was developed and operational characteristics were explored by trial simulation. The primary outcome was headache response at 2 h after treatment. Groups of four treated and two placebo patients were assigned to one dose. Adaptive dose selection was based on response rates of 60% seen with other migraine treatments. If more than 60% of treated patients responded, then the next dose was the next lower dose; otherwise, the dose was increased. A stopping rule of at least five groups at the target dose and at least four groups at that dose with more than 60% response was developed to ensure that a selected dose would be statistically significantly (p=0.05) superior to placebo. Simulations indicated good characteristics in terms of control of type 1 error, sufficient power, modest expected sample size and modest bias in estimation. The trial design is attractive for phase 2 clinical trials when response is acute and simple, ideally binary, placebo comparator is required, and patient accrual is relatively slow allowing for the collection and processing of results as a basis for the adaptive assignment of patients to dose groups. The acute migraine trial based on this design was successful in both proof of concept and dose range selection.
Hall
David B
DB
Department of Biometrics and Data Management, Boehringer Ingelheim Pharmaceuticals, P.O. Box 368, Ridgefield, CT 06877, USA. dhall@rdg.boehringer-ingelheim.com
Meier
Ulrich
U
Diener
Hans-Cristoph
HC
D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D003198:Computer Simulation; D018849:Controlled Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D018579:Patient Selection; D012107:Research Design; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D018170:Sumatriptan / Q000008:administration & dosage* / Q000627:therapeutic use
D017366:Serotonin Receptor Agonists; D018170:Sumatriptan